USANA HEALTH SCIENCES INC. overview

USANA Health Sciences, Inc. (NYSE: USNA) (the “Company”) today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC (“Hiya”) on December 23, 2024. Consequently, the Company’s fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya’s operating results, which were not significant to the Company’s...

USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and fiscal year 2024 results will be released after the close of market on Tuesday, February 25, 2025. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website ( http://ir.usana.com ) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional...

USANA Health Sciences, Inc. (NYSE:USNA), a leading developer and manufacturer of high-quality nutritional supplements, healthy foods and personal care products, today announced that Doug Hekking, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings with investors at the ICR Conference in Orlando, FL on January 13-14, 2025. The fireside chat will begin at 8:00 AM ET on January 13, 2025. A live audio webcast of the fireside chat will be available on USANA’s...

USANA Health Sciences, Inc. (NYSE: USNA) (the “Company,” “USANA”), today announced its acquisition of a 78.8% controlling ownership stake in Hiya Health Products, LLC (“Hiya”), a leading direct-to-consumer provider of high-quality children’s health & wellness products. The $205 million cash transaction closed on December 23, 2024 and is anticipated to be accretive to USANA’s 2025 adjusted EBITDA. For the last twelve months ended September 30, 2024 (unaudited), Hiya generated net...

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 1, 2023. Key Financial & Operating Results Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million...

USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter results will be released after the close of market on Tuesday, July 25, 2023. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website ( http://ir.usana.com ) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following...

USANA Health Sciences, Inc. (NYSE: USNA) today announced its plans to expand into India in the second half of 2023. Expansion into India increases the Company’s global footprint to 25 markets. “USANA’s expansion into India is our first new market in five years and provides an exciting and gratifying opportunity to introduce USANA’s world class health and wellness products to a new country, culture and demographic,” said Jim Brown, President. “We have spent several years of extensive...

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 1, 2023. Key Financial & Operating Results First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022. Generated $13 million of operating cash flow during the...